| Page 2 | Aplastic Anemia and MDS International Foundation

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis

Author(s): 
Pagliuca S, Risitano AM, De Fontbrune FS, Robin M, Iori AP, Marotta S, Michonneau D, Villate A, Desmier D, Socié G, De Latour RP
Primary Author: 
Pagliuca S
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
Nov 2017

No abstract available.

Bone Marrow Diseases: 

Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia

Author(s): 
Lew JL, Fenderson JL, Carmichael MG
Primary Author: 
Lew JL
Journal Title: 
Hawaii J Med Public Health
Original Publication Date: 
Nov 2017

Hypoplastic Myelodysplastic Syndrome (h-MDS) comprises 15% of all MDS and has traditionally been difficult to distinguish from

Bone Marrow Diseases: 

Uji - Existence Time

An eternal buddha[^1] says,

Sometimes[^2] standing on top of the highest peak,
Sometimes moving along the bottom of the deepest ocean.
Sometimes three heads and eight arms,[^3]
Sometimes the sixteen-foot or eight-foot (golden body).[^4]
Sometimes a staff or a whisk,[^5]
Sometimes an outdoor pillar or a stone lantern.[^6]
Sometimes the third son of Chang or the fourth son of Li,
Sometimes the earth and space.

Cover Photo: 

One Bright Pearl (Ikka-no-myoju)

Xuansha, Great Master Zongyi, of Mt. Xuansha, Fu Region, China, of the Saha World, used to be called Shibei. His family name was Xie. When he was a householder, he loved fishing and boating on the Nantai River, doing as fishermen do.  One day at the beginning of the Xiantong Era [860—873] a golden scaled fish came to him without his seeking it, and he suddenly had the urge to leave the dusty world.

Cover Photo: 

Promising new advances in AML therapy

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s): 
Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R
Primary Author: 
Slade M
Journal Title: 
Biology of Blood and Marrow Transplantation
Original Publication Date: 
Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

Author(s): 
Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
Primary Author: 
Ali AM
Journal Title: 
Cancer Med
Original Publication Date: 
Oct 2017

Bone Marrow Diseases: 

Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

Author(s): 
DeZern AE, Binder G, Ni Q, McGuire M, Smith BD
Primary Author: 
DeZern AE
Journal Title: 
Leuk Res
Original Publication Date: 
Oct 2017

Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with

Bone Marrow Diseases: